<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02861404</url>
  </required_header>
  <id_info>
    <org_study_id>BIOVRAIE</org_study_id>
    <nct_id>NCT02861404</nct_id>
  </id_info>
  <brief_title>Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment</brief_title>
  <acronym>BIOVRAIE</acronym>
  <official_title>Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of the study is the evaluation of the role of Human Papilloma Virus&#xD;
      (HPV) in plantar warts (prevalence, genotype), resistant or not, treated or not, cured or&#xD;
      not. This epidemiological study is an ancillary study of the prospective, randomized&#xD;
      controlled, clinical study VRAIE (sponsor: APHP) comparing 5 usual strategies in the&#xD;
      management of plantar warts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of HPV viral DNA on samples</measure>
    <time_frame>up to Day 90</time_frame>
    <description>research of positive HPV status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of viral genotypes</measure>
    <time_frame>up to Day 90</time_frame>
    <description>number of samples containing one or more viral type (type 1, 2, 4 or mix)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission defined</measure>
    <time_frame>up to Day 90</time_frame>
    <description>complete remission of wards confirmed by the physician, no later than day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral remission for patients with wards resistant to treatments</measure>
    <time_frame>up to Day 90</time_frame>
    <description>viral status modification from negative to positive between day 0 and day 30, day 60 or no more than day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse</measure>
    <time_frame>21 months</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">406</enrollment>
  <condition>Plantar Warts</condition>
  <arm_group>
    <arm_group_label>Salicylate ointment</arm_group_label>
    <description>patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <description>patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Fluoro-Uracil</arm_group_label>
    <description>patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <description>patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>skin flakes collection</intervention_name>
    <description>viral status assessment of skin flakes</description>
    <arm_group_label>5-Fluoro-Uracil</arm_group_label>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_label>Salicylate ointment</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        2000 skin flakes to be collected from patients included in VRAIE study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient aged 18 years or more.&#xD;
&#xD;
          -  Clinical evaluation&#xD;
&#xD;
          -  Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10&#xD;
             cm, whether previously treated or not&#xD;
&#xD;
          -  In treated patients, all potentially active treatment on warts since at least one&#xD;
             month should be stopped.&#xD;
&#xD;
          -  Effective contraception for women of childbearing age&#xD;
&#xD;
          -  Immunocompetent patients&#xD;
&#xD;
          -  Patient with one or more warts on soles and board feet.&#xD;
&#xD;
               -  MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less&#xD;
                  thick; after stripping, appear black points, very specific; often painful to&#xD;
                  pressure. They are lonely, single or not. They could regroup galley thick. The&#xD;
                  stripping can them to individualize.&#xD;
&#xD;
               -  Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot.&#xD;
                  Little painful, they are often ignored by the patients when they appear&#xD;
&#xD;
          -  Patient affiliated to the French social security.viral&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient suspected to be immunocompromised&#xD;
&#xD;
          -  Patient aged under 18 years&#xD;
&#xD;
          -  Patient refusing to sign the consent&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Plantar calluses&#xD;
&#xD;
          -  Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream&#xD;
             (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin,&#xD;
             polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl&#xD;
             hydroxybenzoate, xanthan gum, purified water)&#xD;
&#xD;
          -  Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl&#xD;
             alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives:&#xD;
             METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)&#xD;
&#xD;
          -  Contra-indication to Pomade M.O Cochon® (Known allergy to any components)&#xD;
&#xD;
          -  Known hypersensitivity to Blenderm®&#xD;
&#xD;
          -  Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an&#xD;
             extra plantar site)&#xD;
&#xD;
          -  Plantar hyperhidrosis making impossible adhesion of plaster.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Aubin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Foot Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

